Possible Fecal Contamination Prompts Butter Recall
By Stephanie Brown HealthDay Reporter
FRIDAY, April 11, 2025 -- More than 1,700 pounds of butter are being recalled due to possible contamination with coliform, a type of bacteria found in fecal matter, according to the U.S. Food and Drug Administration.
Agri-Mark Inc., a Waitsfield, Vermont, company, is voluntarily recalling 189 cases of Cabot Creamery 8-ounce premium butter made with sea salt. The recall, first issued on March 26, is ongoing and classified as Class III, the lowest level of recall. According to the FDA, a Class III recall is issued when the "use of or exposure to a violative product is not likely to cause adverse health consequences."
Coliform bacteria are common in the environment and in the feces of warm-blooded animals and humans, the Associated Press reported. While these bacteria themselves are usually not harmful, their presence can indicate the potential presence of disease-causing germs.
The butter was distributed in seven states: Arkansas, Connecticut, Maine, New Hampshire, New York, Pennsylvania, and Vermont. Consumers should not eat or use the recalled butter, which can be identified by lot number 090925-055, item number 2038, and a best-by date of Sept. 9.
Agri-Mark has successfully identified the cause of the issue and has already implemented the necessary internal actions to resolve it. No other products were affected, and to date, no complaints of illness related to this product have been reported.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
AAP Updates Screening Guidance for Child Mental Health, Behavioral Problems
MONDAY, Aug. 25, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Aug. 25 in Pediatrics, updated recommendations are presented for...
Discordance Seen Between Care Goals, Treatment Intent in Advanced Cancer
MONDAY, Aug. 25, 2025 -- More patients with advanced cancer report that their treatment discordantly focuses on longevity over comfort than patients with other illnesses...
Apitegromab Improves Motor Function in Spinal Muscular Atrophy
MONDAY, Aug. 25, 2025 -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.